FLOVENT DISKUS Rx
Generic Name and Formulations:
Fluticasone propionate 50mcg/inh, 100mcg/inh, 250mcg/inh; dry pwd for inhalation; blisters with inhalation device.
Indications for FLOVENT DISKUS:
Maintenance treatment of asthma as prophylactic therapy.
Limitations Of use:
Not for the relief of acute bronchospasm.
Previously on bronchodilators alone: initially 100mcg twice daily (approx. 12hrs apart); max 1000mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
<4yrs: not established. 4–11yrs: Previously on bronchodilators alone: initially 50mcg twice daily (approx. 12hrs apart); max 100mcg twice daily. Rinse mouth after use. Titrate to lowest effective dose after stability achieved. Re-evaluate if inadequate control.
Primary treatment of status asthmaticus or other acute attacks requiring intensive measures. Severe milk protein hypersensitivity.
Maintain regular regimen. Infections. If exposed to chickenpox or measles, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Change in vision or history of increased intraocular pressure, glaucoma, and/or cataracts; monitor. Monitor for reduction in bone mineral density if other osteoporosis risk factors exist; and for growth suppression in children; hypercorticism and HPA axis suppression (if occur discontinue gradually). Eosinophilic conditions. Hepatic impairment (monitor). Transferring from oral corticosteroids: see full labeling. Pregnancy. Nursing mothers.
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, ketoconazole): not recommended.
Upper respiratory tract infection/inflammation, throat irritation, sinusitis, rhinitis, oral candidiasis, nausea, vomiting, GI discomfort, fever, cough, bronchitis, headache; immunosuppression, adrenal suppression, bronchospasm, hypersensitivity reactions.
Diskus (60 blisters)—1
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds